<abstract xmlns="http://www.w3.org/1999/xhtml">
<sec id="j_jccm-2022-0013_s_006">
<h3>Aim</h3>
<p>The aim of this study was to evaluate whether systemic immune-inflammation index (SII) could predict mortality in patients with novel coronavirus 2019 (COVID-19) disease.</p></sec>
<sec id="j_jccm-2022-0013_s_007">
<h3>Methods</h3>
<p>This two-center, retrospective study included a total of 191 patients with confirmed diagnosis of COVID-19 via nucleic acid test (NAT). The SII was calculated based on the complete blood parameters (neutrophil × platelet/lymphocyte) during hospitalization. The relationship between the SII and other inflammatory markers and mortality was investigated.</p></sec>
<sec id="j_jccm-2022-0013_s_008">
<h3>Results</h3>
<p>The mortality rate was 18.3%. The mean age was 54.32±17.95 years. The most common symptoms were fever (70.7%) and dry cough (61.3%), while 8 patients (4.2%) were asymptomatic. The most common comorbidities were hypertension (37.7%), diabetes (23.0%), chronic renal failure (14.7%), and heart failure (7.9%) which all significantly increased the mortality rate (p&lt;0.001). There was a highly positive correlation between the SII and polymorphonuclear leukocyte (PNL), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) (r=0.754, p&lt;0.001; r=0.812, p&lt;0.001; r=0.841, p&lt;0.001, respectively), while a moderate, positive correlation was found between the SII and C-reactive protein (CRP) (r=0.439, p&lt;0.001). There was a significant correlation between the SII and mortality (U=1,357, p&lt;0.001). The cut-off value of SII was 618.8 (area under the curve=0.751, p&lt;0.001) with 80.0% sensitivity and 61.5% specificity. A cut-off value of >618.8 was associated with a 4.68-fold higher mortality.</p></sec>
<sec id="j_jccm-2022-0013_s_009">
<h3>Conclusion</h3>
<p>Similar to NLR and PLR, the SII is a proinflammatory marker of systemic inflammation and can be effectively used in independent predicting COVID-19 mortality.</p></sec>
</abstract>

Aim
The aim of this study was to evaluate whether systemic immune-inflammation index (SII) could predict mortality in patients with novel coronavirus 2019 (COVID-19) disease.

Methods
This two-center, retrospective study included a total of 191 patients with confirmed diagnosis of COVID-19 via nucleic acid test (NAT). The SII was calculated based on the complete blood parameters (neutrophil × platelet/lymphocyte) during hospitalization. The relationship between the SII and other inflammatory markers and mortality was investigated.

Results
The mortality rate was 18.3%. The mean age was 54.32±17.95 years. The most common symptoms were fever (70.7%) and dry cough (61.3%), while 8 patients (4.2%) were asymptomatic. The most common comorbidities were hypertension (37.7%), diabetes (23.0%), chronic renal failure (14.7%), and heart failure (7.9%) which all significantly increased the mortality rate (p<0.001). There was a highly positive correlation between the SII and polymorphonuclear leukocyte (PNL), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) (r=0.754, p<0.001; r=0.812, p<0.001; r=0.841, p<0.001, respectively), while a moderate, positive correlation was found between the SII and C-reactive protein (CRP) (r=0.439, p<0.001). There was a significant correlation between the SII and mortality (U=1,357, p<0.001). The cut-off value of SII was 618.8 (area under the curve=0.751, p<0.001) with 80.0% sensitivity and 61.5% specificity. A cut-off value of >618.8 was associated with a 4.68-fold higher mortality.

Conclusion
Similar to NLR and PLR, the SII is a proinflammatory marker of systemic inflammation and can be effectively used in independent predicting COVID-19 mortality.

Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients

The Journal of Critical Care Medicine

This work is licensed under the Creative Commons Attribution 4.0 International License.

Aim
The aim of this study was to evaluate whether systemic immune-inflammation index (SII) could predict mortality in patients with novel coronavirus 2019 (COVID-19) disease.

Methods
This two-center, retrospective study included a total of 191 patients with confirmed diagnosis of COVID-19 via nucleic acid test (NAT). The SII was calculated based on the complete blood parameters (neutrophil × platelet/lymphocyte) during hospitalization. The relationship between the SII and other inflammatory markers and mortality was investigated.

Results
The mortality rate was 18.3%. The mean age was 54.32±17.95 years. The most common symptoms were fever (70.7%) and dry cough (61.3%), while 8 patients (4.2%) were asymptomatic. The most common comorbidities were hypertension (37.7%), diabetes (23.0%), chronic renal failure (14.7%), and heart failure (7.9%) which all significantly increased the mortality rate (p618.8 was associated with a 4.68-fold higher mortality.

Conclusion
Similar to NLR and PLR, the SII is a proinflammatory marker of systemic inflammation and can be effectively used in independent predicting COVID-19 mortality.

Aim
The aim of this study was to evaluate whether systemic immune-inflammation index (SII) could predict mortality in patients with novel coronavirus 2019...

Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients

Article Category: Research article

Pubblicato online: 12 ago 2022

Pagine: 156 - 164

Ricevuto: 31 ott 2021

Accettato: 01 giu 2022

DOI: https://doi.org/10.2478/jccm-2022-0013

Parole chiave
COVID-19, mortality, systemic immune-inflammation index, neutrophil/lymphocyte ratio, inflammatory markers

© 2022 Tahsin Karaaslan, Esra Karaaslan, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients

Article Category: Research article

Pubblicato online: 12 ago 2022

Pagine: 156 - 164

Ricevuto: 31 ott 2021

Accettato: 01 giu 2022

DOI: https://doi.org/10.2478/jccm-2022-0013

Parole chiaveCOVID-19, mortality, systemic immune-inflammation index, neutrophil/lymphocyte ratio, inflammatory markers

© 2022 Tahsin Karaaslan, Esra Karaaslan, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Parole chiave
COVID-19, mortality, systemic immune-inflammation index, neutrophil/lymphocyte ratio, inflammatory markers